NIH Study Links Two Common PFAS to Increased Risk of Aggressive Breast Cancer

November 5, 2026

National Institutes Of Health

At a Glance

Category	Detail
Condition	Clinical topic addressed by the source article: NIH Study Links Two Common PFAS to Increased Risk of Aggressive Breast Cancer
Key Mechanisms	The authors proposed that PFAS could affect risk through non-hormonal pathways, potentially involving altered gene activity or the immune system; the study did not examine these explanations.
Target Population	The PFAS analysis included 1,609 Sister Study participants who subsequently developed breast cancer and 2,269 comparison participants. The broader Sister Study enrolled women ages 35–74 who had a full or half-sister previously diagnosed with breast cancer and no breast cancer diagnosis at enrollment.
Care Setting	Environmental health and cancer epidemiology research; the study assessed associations between blood PFAS concentrations and subsequent breast cancer diagnoses.

Key Highlights

Higher blood plasma concentrations of PFOA and PFOS were associated with increased incidence of ER-negative breast cancer.
Compared with the lowest concentration group, the highest PFOA group had a 67% higher rate of ER-negative breast cancer; the corresponding PFOS rate was 93% higher.
The reported percentages are relative differences between groups, not an individual woman’s probability of developing breast cancer.
No clear association was found between either chemical and overall breast cancer risk.
The investigators confirmed the result through meta-analysis of earlier research; the authors called for further research, including on newer PFAS replacements.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

The authors call for further research, including studies of people with greater PFAS exposure and populations more affected by ER-negative breast cancer; the article provides no clinical monitoring recommendations.

Risks

Patient & Prescribing Data

The PFAS analysis included 1,609 participants who subsequently developed breast cancer and 2,269 comparison participants. The broader Sister Study enrolled women ages 35–74 with no breast cancer diagnosis at enrollment and a full or half-sister previously diagnosed with breast cancer.

No treatment or prescribing data are reported. The article states that individuals can take measures to reduce PFAS exposure but does not specify measures.

Clinical Best Practices

Interpret the reported 67% and 93% differences as relative rates across concentration groups, not as individual absolute risks.
Distinguish the association with ER-negative breast cancer from the absence of a clear association with overall breast cancer risk.
Do not treat the proposed gene-activity or immune pathways as established mechanisms; the study did not examine them.
Recognize that the analysis concerned PFOA and PFOS; the authors state that breast cancer risk associated with newer replacement PFAS requires further study.